Skip Navigation



European Heart Journal Advance Access published online on September 18, 2008
European Heart Journal, doi:10.1093/eurheartj/ehn425
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
29/20/2451    most recent
ehn425v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pitt, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pitt, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

The measurement of plasma aldosterone in patients post-myocardial infarction

Bertram Pitt*

University of Michigan School of Medicine, Ann Arbor, MI 48109, USA

* Corresponding author. Tel:+1 734 936-5260, Fax: +1 734 936 5256. Email: bpitt@umich.edu

This editorial refers to ‘Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction’{dagger} by B.R. Palmer et al., on page 2489

The first 10% of the full text of this article appears below.

Aldosterone blockade, or more correctly mineralocorticoid receptor blockade (MRB), when administered between days 3 and 14 in patients with heart failure (HF) and left ventricular systolic dysfunction (LVSD) post-myocardial infarction (MI) has been shown to reduce all-cause mortality as well as hospitalizations for HF (EPHESUS).1 Of note, all-cause mortality was reduced by 31% at 30 days post-randomization.2 These benefits on mortality were seen in patients with an ST-segment elevation (STE) MI and in those with a non-ST-segment elevation (NST) MI, as well as in patients treated with ‘optimal’ medical therapy including an aspirin, statin, reperfusion, a diuretic, a β-adrenergic receptor blocker, and an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocking agent (ARB). This strategy has been adopted by both the European Society of . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction
Barry R. Palmer, Anna P. Pilbrow, Christopher M. Frampton, Tim G. Yandle, Lorraine Skelton, M. Gary Nicholls, and A. Mark Richards
EHJ 2008 29: 2489-2496. [Abstract] [FREE Full Text]